Mirati Therapeutics Inc. (NASDAQ:MRTX) has been given a consensus recommendation of “Buy” by the ten research firms that are presently covering the firm. Four equities research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $22.77.
MRTX has been the topic of a number of research analyst reports. Zacks Investment Research lowered shares of Mirati Therapeutics from a “hold” rating to a “sell” rating in a research note on Wednesday, July 6th. Piper Jaffray Cos. reissued a “neutral” rating and issued a $7.00 price target (down from $14.00) on shares of Mirati Therapeutics in a report on Monday, August 8th. Finally, Wedbush reissued an “outperform” rating and issued a $12.00 price target on shares of Mirati Therapeutics in a report on Tuesday, October 4th.
Several institutional investors have recently added to or reduced their stakes in the company. KCG Holdings Inc. purchased a new position in shares of Mirati Therapeutics during the second quarter valued at about $102,000. Citadel Advisors LLC increased its position in shares of Mirati Therapeutics by 72.3% in the second quarter. Citadel Advisors LLC now owns 22,064 shares of the company’s stock valued at $120,000 after buying an additional 9,258 shares in the last quarter. Alliancebernstein L.P. purchased a new position in shares of Mirati Therapeutics during the second quarter valued at about $125,000. California State Teachers Retirement System increased its position in shares of Mirati Therapeutics by 9.5% in the second quarter. California State Teachers Retirement System now owns 26,594 shares of the company’s stock valued at $145,000 after buying an additional 2,300 shares in the last quarter. Finally, Quantitative Systematic Strategies LLC purchased a new position in shares of Mirati Therapeutics during the second quarter valued at about $165,000. 69.40% of the stock is owned by institutional investors.
Mirati Therapeutics (NASDAQ:MRTX) traded down 3.53% on Friday, reaching $5.19. 112,277 shares of the company’s stock traded hands. Mirati Therapeutics has a 52-week low of $4.40 and a 52-week high of $43.20. The firm’s 50-day moving average is $5.56 and its 200 day moving average is $10.61. The stock’s market capitalization is $103.41 million.
Mirati Therapeutics (NASDAQ:MRTX) last posted its earnings results on Thursday, August 4th. The company reported ($1.11) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.15) by $0.04. Analysts forecast that Mirati Therapeutics will post ($4.45) EPS for the current year.
Mirati Therapeutics Company Profile
Receive News & Ratings for Mirati Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirati Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.